Xinlitai (002294.SZ): Alisartan ester chlorthalidone sustained-release tablets obtained drug registration certificate.

Financial news app Zhitong reported that Xintai (002294.SZ) announced that the company has received the drug registration certificate for Alisartan ester and Ivabradine sustained-release tablets (Fulian) issued by the National Medical Products Administration. Alisartan ester and Ivabradine sustained-release tablets (Fulian) are used for the treatment of primary hypertension.